NeoPharm is a publicly traded biopharmaceutical company engaged in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases.
NeoPharm has built its drug development program around two proprietary technology platforms: a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid® liposomal drug delivery system.
The company has advanced five drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis, or IPF, and asthma. NeoPharm's stock is traded over-the-counter (OTC) under the stock symbol NEOL.PK.
NeoPharm's corporate office and research and development facility is located in Lake Bluff, Illinois.
NeoPharm’s new management team, enlisted in March of 2007, has undertaken a concentrated plan.
Company Details
- Address
- And Research And Development Facility Is Located In Lake Bluff
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- neopharm.com
Neopharm, Inc. Questions
Neopharm, Inc.'s website is neopharm.com
Neopharm, Inc.'s LinkedIn profile is https://www.linkedin.com/company/neopharm-inc.
Neopharm, Inc.'s industry is
Pharmaceutical Manufacturing
Neopharm, Inc.'s top competitors are
Medisal Pharma - Medisal For Pharmaceuticals Industry Llc,
Neopharm Group,
Lifepharma,
Neopharm Bulgaria Ltd,
Bausch Health Companies Inc.,
Neopharm Boston,
Neopharm Labs,
Neopharm,
Neopharma,
Neopharm Israel.
Neopharm, Inc.'s categories are Pharmaceutical Manufacturing
